Xiang Zhou

8PUBLICATIONS
50CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersMedical mycologyPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 05, 2026
Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms.

Xiang Zhou, Julia Mersi, Christine Riedhammer

|Feb 13, 2026
Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy.

Jan H Frenking, Christine Riedhammer, Thomas Hielscher

|Jan 24, 2026
Cytokine Dynamics in Bortezomib-Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans.

Nadine Cebulla, Daniel Schirmer, Eva Runau

|Dec 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

Lukas Scheller, Xiang Zhou, Henry Loeffler-Wirth

|Jan 24, 2025
Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple Myeloma.

Xiang Zhou, Annika Hofmann, Benedict Engel

|Jul 12, 2024
Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.

Larissa Haertle, Umair Munawar, Hipólito N C Hernández

Pageof 2

Frequent Collaborators

5 joint publications

K Martin Kortüm

3 joint publications

Hermann Einsele

2 joint publications

Larissa Haertle

2 joint publications

Santiago Barrio